Rating Card

premium

Unlock Expert's Rating and Top Picks Portfolio

Curated by Michael O'Reilly since 2020
1550+ opinions with 4.81 rating (one of the best performing expert)

Latest Top Picks

Stock Opinions by Lorne Steinberg

COMMENT

There's value outside North America as the valuation gap between US stocks and ex-US wider than ever. Add to that the strong USD, so those foreign companies are cheap. He likes Japan, UK, and Europe, though many do business in the US. 2025 Canadian outlook: bullish because of further interest rate cuts, and Canada is dividend-driven.

Unknown
WATCH
Merck & Company

It's cheap at 11x forward PE and pays a 3% dividend. Their vaccine business in China has been hurt, but should recover next year. He's looking at it. Likes their drug pipeline.

biotechnology / pharmaceutical
DON'T BUY
Medtronic Inc

It's gone from a market darling to loser, trading at a 10-year low now. It's a show-me stock, though cheap at 15x PE. If the company can grow 5%, maybe it's worth buying. They need to work out some issues first.

biotechnology / pharmaceutical
DON'T BUY
Uber

Too expensive at a high valuation and doesn't offer enough value. Their Uber Eats succeeded, though, and the company will continue to grow. Management keeps on delivering.

Technology
HOLD
Becton Dickinson

90% of their products are disposable medical supplies. Problem was that during Covid, there were fewer operations, so sales fell and are slowing catching up--8-10% growth annually in the next few years, he thinks. Stock is cheap now, but the stock has done nothing for him. Has excellent prospects.

Healthcare
COMMENT
Manulife Financial
Hold and watch it continue to climb without risk?

No, you can never do that. Remember that MFC plunged during 2008 because it got into all kinds of trouble. Today, management has learned a lot from that. He sees big upside in their insurance, US and Asian operations. Still offers decent value and dividend growth. However, insurance companies are prone to serious slides if they make a bad misjudgement.

insurance
DON'T BUY
Novo-Nordisk

They carry one mega-drug, so other competitors are already putting out their own weight-loss drug. He prefers Merck for its lower PE and better pipeline--not better, but safer.

biotechnology / pharmaceutical
BUY
Brookfield Corp

Prefers this to BAM, which BN owns as well as many private assets. The CEO holds a lot of stock, too. 

investment companies / funds
HOLD
BCE Inc.

He won't add now. The dividend is over 10%; the company says it's safe, but the market disagrees, as shares decline. It may make sense for BCE to cut the dividend to pay down debt, but he's comfortable owning this. It's likely bottoming now, but don't buy it now to collect the dividend for the next 5 years (because it could get cut). No, he doesn't like the US acquisition and hopes management sees value in it.

telephone utilities
COMMENT
A Comment -- General Comments From an Expert
natural gas

He doesn't like the sector and he expects natural gas prices to trade off a little. Wait and see with energy as a whole. Nat gas stocks are too high given the nat gas price, and he expects a pullback and opportunities.

Unknown
DON'T BUY
Pfizer Inc

Despite buying a bunch of mega-companies, it remains cheaper than 30 years ago. But it has totally failed to deliver shareholder value. The dividend is safe. 

biotechnology / pharmaceutical
DON'T BUY
Sony Corp. ADR

Not great over the years, suffering from a bloated infrastructure and lacking focus, like many Japanese companies. It should be split into a few companies.

electrical / electronic
PAST TOP PICK
(A Top Pick Oct 20/23, Up 103%)

It was undervalued, forgotten. Management has done a great job. Shares remain cheap as it pays a 4% dividend. Still likes it and would buy it now.

banks
PAST TOP PICK
Kenvue
(A Top Pick Oct 20/23, Up 21%)

An activist investor is inside the company now. Pays a 3.5% dividend. Not followed that much by Wall Street, but offers decent growth.

Consumer Products
PAST TOP PICK
Kering
(A Top Pick Oct 20/23, Down 38%)

The problem is that Gucci continues to underperform; they changed designers. Has huge free cash flow, a good balance sheet and pays a 5.5% dividend. Disappointing.

clothing stores
Showing 1 to 15 of 1,808 entries